Though different study populations, post-hoc analysis of ASSURE showed that RVX-208 combined with rosuvastatin decreased percent atheroma volume by 1.43% in 6 months.

FURTHER ANALYSIS OF THE ASSURE DATA FINDS A RESPONDER GROUP FOR RVX-208 WITH STATISTICALLY SIGNIFICANT REGRESSION OF CORONARY ATHEROSCLEROSIS

Also, remember that the target population for RVX-208 are those with low-HDL, and the target population for the PCSK9 therapies are those with uncontrolled LDL. Further LDL lowering by anti-PCSK9 therapy may still benefit those patients taking RVX-208, and RVX-208 therapy may still benefit those on anti-PCSK9 therapy.

BearDownAZ